Comparative Pharmacology
Head-to-head clinical analysis: IOPAMIDOL 200 IN PLASTIC CONTAINER versus OXILAN 350.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IOPAMIDOL 200 IN PLASTIC CONTAINER versus OXILAN 350.
IOPAMIDOL-200 IN PLASTIC CONTAINER vs OXILAN-350
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iopamidol is a nonionic, water-soluble iodinated radiographic contrast agent that attenuates X-rays by increasing the density of tissues, thereby enhancing vascular and tissue contrast during imaging procedures.
Iodinated contrast medium that attenuates X-rays due to its iodine content, enhancing vascular and tissue contrast during imaging. It distributes in extracellular fluid and is freely filtered by glomeruli.
Intravascular administration: 1-2 mL/kg (200 mg I/mL) intravenously, up to a maximum of 150 mL per diagnostic procedure. Intraarterial administration: varies by procedure; typical 5-60 mL per injection.
Intravenous: 0.5–2 mL/kg (350 mg I/mL) for CT imaging; maximum 200 mL total. Intra-arterial: 0.3–1.5 mL/kg per injection; maximum 200 mL per procedure.
None Documented
None Documented
Terminal elimination half-life approximately 2 hours (range 1.5-2.5 hours) in patients with normal renal function; prolonged in renal impairment.
Terminal elimination half-life: 2 hours (normal renal function); prolonged in renal impairment (up to 24 hours in severe impairment).
Primarily renal (99% unchanged in urine within 24 hours). Biliary/fecal excretion <1%.
Renal: >90% unchanged drug within 24 hours; Biliary/fecal: <2%
Category C
Category C
Radiocontrast Agent
Radiocontrast Agent